Abstract. Puerarin has attracted increasing attention because of its beneficial effects on anti-osteoporosis, but the molecular mechanisms underlying its actions on osteoblasts are not fully understood. The current study aimed to investigate the effect of puerarin on the cell viability and differentiation of mouse MC3T3-E1 osteoblast-like cells in vitro and its underlying mechanisms. The results indicated that 0.01, 0.1 and 1 mg/ml puerarin significantly promoted the viability of osteoblasts, enhanced alkaline phosphatase (ALP) activity and increased the expression of transforming growth factor-β1, Smad2, Smad3 and Runt-related transcription factor (Runx)2. Micro (mi)RNA target prediction programs predicted that miR-204 may directly target Runx2. Following treatment with 0.1 mg/ml puerarin for 48 h, the expression level of miR-204 was downregulated. Besides, miR-204 dramatically repressed the luciferase activity of wildtype Runx2 3'-UTR transfected cells, but not that of the mutant ones. Overexpression of miR-204 in osteoblasts significantly decreased the protein expression of Runx2, while inhibition of miR-204 enhanced Runx2's expression. In addition, overexpression of miR-204 inhibited the cell viability and ALP activity of osteoblasts, while inhibition of miR-204 had the opposite effect. The results suggested that puerarin may promote MC3T3-E1 osteoblast-like cell viability and differentiation, which may be related to the downregulation of miR-204 and the following activation of Runx2.
Introduction
Osteoporosis is a chronic metabolic disease, defined as a skeletal disorder characterized by low bone mass density and microarchitectural deterioration, which predisposes patients to fracture (1) . It is generally believed that osteoporosis is the failure of dynamic balance between the osteoblastic bone formation and osteoclastic bone resorption, and the functional activities of osteoblasts serve a crucial role in the occurrence and development of osteoporosis (2, 3) . Runt-related transcription factor 2 (Runx2), a master bone growth regulatory factor, has been thought to be involved in the proliferation and differentiation of osteoblasts (4, 5) . Studies have reported that physiologic levels of Runx2 may promote osteoblast function, while abnormal expression of Runx2 cause the occurrence of bone related diseases (6, 7) . Puerarin is an important isoflavonoid phytoestrogen extracted from the root of Radix Puerariae, which is widely prescribed for patients in China. Studies demonstrated that puerarin could promote the proliferation, differentiation and mineralization of osteoblasts in vitro (8, 9) . Previous studies of the authors have also suggested that puerarin may promote the bone formation in MC3T3-E1 osteoblast-like cells (10, 11) . In a recent report, puerarin was demonstrated to ameliorate bone loss in estrogen-deficient rats, which indicated that puerarin had good anti-osteoporotic effect and may prevent osteoporosis for postmenopausal women (12) . Although experiments have indicated that puerarin served an important role in osteoblasts and osteoporosis in vivo and in vitro, the exact anti-osteoporotic mechanism of puerarin remains unclear.
MicroRNAs (miRs) are small single-stranded non-coding RNAs, 18-22 nucleotides in length, which have emerged as a class of important gene regulators on cellular functions in recent years (13) . They are known to suppress protein expression by binding to the 3'-untranslated region (UTR) of their target mRNAs (14) . It has been suggested that miRNAs may be involved in regulating cell proliferation, differentiation and apoptosis by targeting their downstream genes (15, 16) . However, specific miRNAs in the regulation of osteoblasts activities have not been well characterized and the mechanisms by which these miRNAs target gene expression in osteoblasts remain elucidated.
In the present study, the promoting effects of puerarin on osteoblasts viability and differentiation were examined and the authors indicated that the expression of Runx2 was significantly increased in osteoblasts following puerarin treatment, while that of miR-204 was downregulated. Following this, the authors explored the underlying target relationship between miR-204 and Runx2 using a dual luciferase reporter gene assay. Furthermore, by modulating miR-204 activity, overexpression of miR-204 was markedly decreased the protein level of Runx2, whereas miR-204 inhibition reversed the effect, indicating that Runx2 was a direct target gene of miR-204. Together, these findings suggested that puerarin promotes the viability and differentiation of MC3T3-E1 cells by increasing the expression of Runx2 via miR-204 downregulation.
Materials and methods
Osteoblast culture. MC3T3-E1 cells were purchased from the Shanghai Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in 25 cm 2 flasks in α-modified Eagle's medium (α-MEM; Wisent Inc., St. Bruno, QC, Canada) supplemented with 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin, maintained at 37˚C in a humidified 5% CO 2 incubator (Sanyo Electric Co., Ltd., Moriguchi, Japan).
MTT assay on osteoblasts viability. Briefly, 5x10
3 cells/well were seeded in 96-well culture plates (Corning Incorporated, Corning, NY, USA). The cell culture medium was discarded after 24 h, and 180 µl different final concentrations (0.01, 0.1 and 1 mg/ml) puerarin were added to the experimental wells, while an equal volume of serum-free medium was added to the control wells. Following culturing for 24, 48 and 72 h, the proliferation of osteoblasts was measured by adding 20 µl MTT (5 mg/ml, Amresco LLC, Solon, OH, USA) in each well and incubating for another 4 h. A total of 150 µl dimethyl sulfoxide was added in each well. Following this, the supernatant was removed and absorbance was measured at 490 nm after oscillation for 10 min using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). The viability of osteoblasts after transfection with miR-204 mimics, inhibitor or miR negative control was also examined using MTT assay.
Alkaline phosphatase (ALP) activity expression of osteoblasts. Osteoblasts were cultured in a 24-well culture plate. Following treatment with different final concentrations (0.01, 0.1 and 1 mg/ml) puerarin for 48 h, cells were washed three times with PBS. The ALP positive cells were stained and ALP activity was assayed using a commercial kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions. The ALP activities were also examined in osteoblasts following transfection with miR-204 mimics, inhibitor or miR negative control.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Osteoblasts were seeded in a 24-well plate in α-MEM (Wisent, Inc.), supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), at the density of 1x10 5 cells/well. The concentration of 0.01, 0.1 and 1 mg/ml puerarin was added to the experimental wells, and cultured in a humidified 5% CO 2 incubator at 37˚C for 48 h. Total RNA was prepared using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Purity and concentration of the isolated RNA were detected by a nucleic acid protein analyzer (BioDrop µLite; Biodrop, Cambridge, UK). The RNA was then reversed-transcribed to cDNA with a reverse transcription kit (Takara Bio, Inc., Otsu, Japan), following the manufacturer's protocol. The final reaction solution (25 µl) contained 2 µl cDNA product, 12.5 µl 2X Realtime PCR SYBR premix (Takara Bio, Inc.), 0.5 µl each of forward and reverse primers and 9.5 µl distilled water. The two-step PCR amplification conditions were: Pre-denaturation of 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec, 60˚C for 34 sec. The fluorescence signal detection was measured by Mx3000P real-time PCR system (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA). Target genes included transforming growth factor (TGF)-β1, Smad2, Smad3 and Runx2, while β-actin served as an internal control. Primers were designed and synthesized by GenScript (Piscataway NJ, USA) and are presented in Table I .
Western blot analysis. Protein was extracted from the cells with total protein extraction kit (cat. no. BC3710; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) after treatment with 0.01, 0.1 and 1 mg/ml puerarin for 48 h, and then the protein content was measured by the bicinchoninic acid assay method, according to the manufacturer's instructions (cat. no. PC0020; Beijing Solarbio Science & Technology Co., Ltd.). For western blot analysis, 25 µg of samples were subjected to SDS-PAGE gel and electro-transferred onto a polyvinylidene difluoride membrane. The membrane was then blocked with 5% skim milk in TBS containing 0.1% Tween-20 (TBST) for 1 h at room temperature. Following washing three times in TBST for 5 min, the protein samples were incubated with primary antibodies (Cell Signaling Technology, Inc., Danvers, MA, USA) for TGF-β1 (cat. no. 709), Smad2 (cat. no. 3122), Smad3 (cat. no. 9523), Runx2 (cat. no. 12556) and β-actin (cat. no. 4970; all 1:1,000) at 4˚C overnight. Following washing another three times with TBST, the samples were incubated with horseradish peroxidase-conjugated anti-rabbit IgG secondary antibodies (cat. no. 7074; 1:3,000; Cell Signaling Technology, Inc.) for 1 h at room temperature. Following a final wash of TBST, the protein bands of interest were visualized by the enhanced chemiluminescence detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The intensity of the bands was measured using the ImageJ2x v2.1.4.7 software (National Institutes of Health, Bethesda, MD, USA) to assess the relative protein levels.
Expression profile analysis of miRNAs. Expression profiles analysis of miRNAs was performed by KangChen Biology Engineering Co., Ltd. (Shanghai, China) following treatment of osteoblasts with 0.1 mg/ml puerarin for 48 h.
Network prediction for Runx2-targeting miRNAs. The Runx2-targeting miRNAs were predicted using TargetScan (http://genes.mit.edu/targetscan), PicTar (http://pictar.bio.nyu .edu), miRBase (http://mirbase.org/) and miRDB (http://mirdb .org/miRDB/) programs, and then compared with the results of expression profile analysis to determine the Runx2-targeting miRNAs.
Validation of Runx2-targeting miRNA by RT-qPCR. Following incubating osteoblasts with puerarin (0.1 mg/ml) for 48 h, total RNA was extracted using TRIzol reagent (Takara Bio, Inc.). Dual luciferase reporter gene assay. Osteoblasts were seeded in 24-well plates at a density of 2x10 4 per well. At 24 h incubation, cells in each well were transfected with the recombinations of wildtype Runx2 3'-UTR or mutant Runx2 3'-UTR plasmids (100 ng) and miR-204 mimics (2 µM) or miR control (2 µM) using Lipofectamine 2000 (1 ml; Invitrogen; Thermo Fisher Scientific, Inc.). Cells were collected following 48 h transfection, then firefly and Renilla luciferase activities were analyzed using Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA). The ratio of firefly to Renilla luciferase activity was used as relative luciferase activity.
Overexpression and inhibition of miR-204. The mouse miR-204 mimics, miR-204 inhibitor and negative control were obtained from Shanghai GenePharma Co., Ltd. Cells were seeded in six-well plates at a density of 1x10 5 
Statistical analysis.
The results were presented as mean ± standard deviation. Data comparisons were analyzed by Student's t-test or one-way analysis of variance with SPSS software (version, 17.0; SPSS Inc., Chicago, IL, USA). Comparisons between groups were analyzed using the Bonferroni post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results

Puerarin promotes osteoblast viability and differentiation.
The authors first examined whether puerarin could affect osteoblast viability. Osteoblasts were cultured with puerarin at various concentrations. The cells treated with puerarin had significantly higher viability compared with that of the control cells (P<0.05), except those treated with puerarin at a lower concentration (0.01 mg/ml) for 24 h and 48 h (Fig. 1A) . The osteoblasts treated with puerarin for 48 h at various concentrations (0.01, 0.1 and 1 mg/ml) had significantly higher ALP activity than that of the control cells (P<0.05; Fig. 1B ). These data suggested that puerarin may promote osteoblast viability and differentiation.
Puerarin increases the expression of TGF-β1, Smad2, Smad3 and Runx2. In order to explore the proliferation effect of puerarin on osteoblasts, the authors studied the expression of osteoblast-related regulatory factors (TGF-β1, Smad2, Smad3 and Runx2). Following treating cells with puerarin for 48 h, we measured TGF-β1, Smad2, Smad3 and Runx2 gene expression with RT-qPCR and also the protein expression with western blotting. The transcription levels and the translation levels of the genes were all significantly increased in the cells treated with puerarin (P<0.05; Fig. 2 ). The data imply that these factors may be involved in the promotion effects of puerarin on osteoblasts. Studies have indicated that Runx2 is a master regulatory factor that serves a crucial role on the regulation of transcription in osteoblasts. Afterwards, the authors focused on the expression of Runx2-targeting miRNAs (17) .
Puerarin downregulates the expression of miR-204.
Analysis of miRNA expression profiles demonstrated that the expression of miR-204 and other 118 miRNAs changed following puerarin treatment for 48 h (18) . In addition, miRNA target analysis programs (TargetScan, PicTar, miRBase and miRDB) predicted that miR-204 may directly target the osteogenic crucial regulator Runx2. Then, the effect of puerarin on miR-204 expression was examined by stem-loop RT-qPCR. The expression level of miR-204 was significantly decreased following culturing the cells with 0.1 mg/ml puerarin for 48 h, compared with that of the cells in absence of puerarin (P<0.05; Fig. 3A) . The results suggested that puerarin downregulated the expression of miR-204. Combined with the previous validation that puerarin promoted osteoblast viability and differentiation through upregulation of Runx2, however, the authors demonstrated that miR-204 was downregulated. Moreover, according to the bioinformatics analysis, miR-204 was suggested to bind to the 3'-UTR of Runx2 through specific binding sites (Fig. 3B ). Taken together, future studies are prompted to determine whether Runx2 is a direct downstream target of miR-204.
Runx2 is the target of miR-204 in mouse osteoblasts.
To further investigate whether Runx2 can be directly targeted by miR-204, luciferase reporters containing wildtype or mutant 3'-UTR of Runx2 were engineering and transfected with miR-204 mimics or miR negative control. As presented in Fig. 4A , transfection with miR-204 mimics of wildtype-Runx2-3'-UTR recombinant plasmid had lower luciferase activity compared with that of the miR negative control, while transfection with miR-204 mimics of mutant-Runx2-3'-UTR recombinant plasmid had no statistically significant difference compared with that of the miR negative control. These data indicated that miR-204 dramatically repressed the luciferase activity of the reporter containing the wild-type full-length 3'-UTR of Runx2, but not the mutant full-length 3'-UTR of Runx2, implying that miR-204 may directly target Runx2.
The effects of overexpression and inhibition of miR-204 on Runx2 were then investigated. The expression of Runx2 was analyzed using RT-qPCR and western blotting methods in osteoblasts at 48 h following transfection with miR-204 mimics, inhibitor or miR negative control. The results of RT-qPCR (Fig. 4B) did not show significant difference, but western blotting analysis (Figs. 4C and D) indicated that overexpression of miR-204 in osteoblasts significantly decreased the expression level of Runx2, while inhibition of miR-204 had the opposite effect. The effects of alternation on protein level, rather than on mRNA level, suggesting that a role of miR-204 for post-transcriptional regulation. Collectively, these results indicated that Runx2 is a direct target of miR-204.
miR-204 inhibits the viability and differentiation of osteoblasts.
Finally, the authors investigated the effect of miR-204 on osteoblasts. Following transfection with miR-204 mimics, inhibitor or miR negative control for 48 h, the viability and ALP activity of osteoblasts were tested. The cells that were transfected with miR-204 mimics had significantly lower viability, but cells transfected with miR-204 inhibitor had higher viability compared with that of the control cells (Fig. 5A) . Similarly, transfection with miR-204 mimics significantly reduced ALP activity, whereas transfection with miR-204 inhibitor had the opposite effect (Fig. 5B) . These results suggested that miR-204 may inhibit osteoblast viability and differentiation.
Discussion
Runx2 is an important bone regulatory factor, which serves a crucial role in the regulation of transcription in osteoblasts. Puerarin was reported to promote the proliferation and osteoblastic differentiation in human bone marrow stromal cells by increasing the expression of osteoblastic markers, including Runx2 (19) . Runx2, BMP-2 and OPG gene expression was found to be upregulated following treating mouse osteoblasts 1x10 -8 mol/l puerarin (20) . However, other research reported that puerarin significantly increased the expression of ALP, OPG and RANKL, but not Runx2 in UMR106 cells (8) . In addition, puerarin increased the mRNA levels of osteoblast differentiation markers, such as ALP and type I collagen, but not Runx2 or osterixin in primary baboon osteoblasts (21) . Obviously, the effects of puerarin on Runx2 in different cells remains a controversial issue. In the current study, puerarin significantly increased the expression of Runx2 in osteoblast-like MC3T3-E1 cells, and the further study demonstrated that miR-204 was involved in the regulatory mechanism.
miRNAs are a large family of small non-coding RNAs that regulate gene expression. miR-204, a negative regulator, is involved in the regulation of many biological activities. It is validated that the expression of miR-204 is downregulated in bone tissue of ovariectomized mice (22) and it is also reported miR-204 has no effect on bone formation in vivo (23) . However, miR-204 has received little attention in osteoblast viability and differentiation in vitro. In the present study, puerarin promoted the viability and differentiation of osteoblasts, and correspondingly increased the expression of In the current study, the authors observed and explored the change of Runx2 targeted by miR-204; however, some other osteoblast-related regulatory factors such as TGF-β1, Smad2 and Smad3 were upregulated following treatment of puerarin. Although miR-204 could not directly target these factors based on software prediction and bioinformatics analysis, it has been revealed that miRNAs usually function in clusters (26) . The mechanism whether the other varied miRNAs among the miRNA expression profiles after puerarin treatment has effects on TGF-β1, Smad2 and Smad3 remains unknown. In fact, studies have indicated that Runx2, TGF-β1, Smad2 and Smad3 are capable of regulating the expression of miRNAs directly or indirectly (27) (28) (29) , suggesting that regulatory factors and miRNAs are not independent and they regulate each other bidirectionally. In view of the promoting effect of puerarin on cellular viability and differentiation, its regulatory effects on miR-204 and the downstream target Runx2, the detailed upstream signaling pathway by which puerarin affects miR-204 downregulation is still unknown, which remains to be elucidated. Besides, further research on human osteoblasts is required to further confirm these findings because of the differences between mouse and human cells.
In conclusion, the authors demonstrated that puerarin significantly promoted the viability and differentiation of osteoblasts. Following treatment with puerarin in mouse osteoblasts, the expression level of Runx2 was significantly increased, which was negatively correlated with that of miR-204, whose expression level was decreased. Moreover, the current study demonstrated that miR-204 could directly target Runx2; Runx2 was identified as a target of miR-204. The results suggested that puerarin promoted the viability and differentiation of mouse osteoblasts by increasing the expression of Runx2 via miR-204 downregulation. These findings provide a better understanding of the biological effects of puerarin on bone formation in vitro, and suggested the potential use of puerarin in prevention and treatment of osteoporosis.
